[Discussion] amylin is doing more work than we give it credit for
amylin is doing more work than we give it credit for. Not a hot take, just something I have not seen said plainly here. Sent a vial to Medutest because there was almost nothing on file for this compound. 99.5% against a claimed 99.0%, and I posted it because the log needs entries. The tolerability tables were more…
Cosigning on the thin independent data. Fewer members test this, so the bands are wider and should be treated that way.
Cosigning on the thin independent data.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
satiety signalling rather than incretin signalling
independent purity data on this compound is thin
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
nothing containing this is approved as a standalone product
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.